We are pleased to announce a major regulatory milestone—our in vitro diagnostic (IVD) solution for kidney function assessment has officially received approval from the Singapore Health Sciences Authority (HSA).
This important achievement marks a key step in expanding our international presence and underscores our ongoing commitment to advancing diagnostics for chronic kidney disease (CKD).
With this regulatory approval, we are now able to provide healthcare professionals in Singapore with an innovative diagnostic technology that supports more timely and precise evaluation of kidney function—potentially improving patient outcomes.
This milestone reaffirms the quality and reliability of our solutions and demonstrates our ability to meet the stringent regulatory requirements set forth by the Singaporean authorities.
It also strengthens the foundation of our global diagnostic portfolio and highlights our dedication to international growth.
We sincerely thank our dedicated team members and valued partners whose support made this accomplishment possible.
We will continue to develop and deliver high-quality diagnostic products, with this approval serving as a catalyst for further global expansion and innovation in kidney health diagnostics.
